Highest-materiality recent filing
Vicarious Surgical shareholders approve reverse stock split at ratio of 1:2 to 1:30
Over 11.8M votes in favor, 49,675 against, 3,430 abstentions at April 8 special meeting.
Vicarious Surgical reports Q4 net loss $10.5M; NYSE delisting, now on OTCID
Q4 GAAP net loss $10.5M ($1.57/sh) vs $13.9M ($2.36/sh) YoY; FY2025 net loss $50.2M ($8.19/sh) vs $63.2M ($10.74/sh) YoY.
Vicarious Surgical NYSE delisting; President and CTO take salary cuts
NYSE commenced delisting proceedings on March 3, 2026; stock now quoted on OTC under RBOT.
Vicarious Surgical receives NYSE delisting notice; trading suspended, moves to OTCID
NYSE notified Vicarious Surgical on Mar 3, 2026 of delisting for falling below $15M avg mkt cap over 30 trading days.
Vicarious Surgical amends CEO severance, enters CFO severance agreement
CEO Stephen From severance without cause: 1 yr base salary + pro-rata bonus + 12 mos COBRA.
Vicarious Surgical shareholders approve exercise of Oct 2025 warrants for 2.3M shares
Special meeting held Jan 9, 2026; quorum of 78.18% of total voting power present.
Vicarious Surgical guides FY2026 cash burn ~$35M (improved from $45M); NYSE to delist warrants
FY2026 cash burn guidance of ~$35M, a $10M improvement over the recently updated $45M 2025 guidance.
Vicarious Surgical cuts 2025 cash burn outlook to ~$45M, improves by $5M
Full-year 2025 cash burn guidance improved to ~$45M from prior $50M, reflecting cost management.
Vicarious Surgical reports Q3 2025 net loss of $11.1M, down from $17.1M year-over-year
Total operating expenses fell 35% to $11.5M from $17.8M in Q3 2024
Vicarious Surgical prices $5.9M registered direct offering and private placement at $5.10/unit
Offering comprises 1,150,000 shares (or pre-funded warrants) and Series A & B warrants for up to 2,300,000 shares at $5.10 exercise price.
Vicarious Surgical appoints Joseph Doherty as Chairman of the Board
Doherty appointed Chairman effective Sept 25, 2025; he joined the Board in June 2025.
Controlled builds completed in April and August 2025 under full QMS, demonstrating reproducibility and scalability.
Director Donald Tang resigns; Victoria Carr-Brendel joins audit committee
Donald Tang resigned from the board effective September 12, 2025, not due to any disagreement.
First build under control completed April 2025; second build completed August 2025 demonstrating scalability.
Vicarious Surgical Q2 net loss narrows to $13.2M; CEO transition to Stephen From
GAAP net loss of $13.2M ($2.23/share) vs. $15.2M ($2.59/share) in Q2 2024.
Vicarious Surgical appoints Stephen From as CEO, Adam Sachs becomes President
Stephen From appointed CEO effective Aug 7, 2025; also joins Board.
Vicarious Surgical's NYSE compliance plan accepted; auditor changed to Cherry Bekaert
NYSE accepted compliance plan to regain $50M min market cap within 18 months; RBOT now trades with '.BC' indicator.
Vicarious Surgical elects Fuad Ahmad and Joseph Doherty to board; Ric Fulop departs
Fuad Ahmad (former CFO of Iridex, Mitek, Vaxart) and Joseph Doherty (CEO Worcester City Campus, former Olympus/J&J) elected at annual meeting.
Vicarious Surgical Q1 2025: GAAP net loss $15.4M; FY cash burn guided ~$50M
GAAP net loss $15.4M ($2.60/shr) vs $17.0M ($2.90) Q1 2024; adjusted net loss $15.3M ($2.58/shr).
Vicarious Surgical receives NYSE delisting notice for low market cap and equity
30-day avg market cap ~$47.4M and stockholders' equity $46.7M as of Dec 31, 2024.
Vicarious Surgical President Randy Clark resigns, appointed to Board effective April 25
President Randy Clark will resign effective April 25, 2025, and be appointed to the Board pending conflict checks.
FY2024 GAAP net loss $63.2M ($10.74/share), adjusted net loss $63.3M ($10.75/share); Q4 GAAP net loss $13.9M.
Vicarious Surgical Appoints Sarah Romano as CFO Effective April 1, 2025
Sarah Romano named CFO and Treasurer, effective April 1, 2025; succeeds prior CFO? Not disclosed.
COO John Mazzola to retire April 1, 2025; responsibilities to President Randy Clark
John Mazzola to retire as COO effective April 1, 2025, after nearly 40 years in healthcare.
Vicarious Surgical enters consulting agreement with former CFO William Kelly through 2028
William Kelly departed as CFO; consulting from Jan 2, 2025 to Dec 31, 2028.
Vicarious Surgical CFO William Kelly resigns effective Jan 2, 2025; succession search underway
William Kelly steps down as CFO after nearly 4 years (since Jan 2021) to pursue other opportunities.
Vicarious Surgical Q3 net loss $17.1M; cash $60.9M; on track for system milestone
GAAP net loss of $17.1M ($2.90/share); adjusted net loss $17.0M ($2.87/share), improved from $20.4M loss YoY.
Vicarious Surgical Q2 net loss $15.2M; cash burn $10.9M, reiterates FY2024 ~$50M
GAAP net loss $15.2M ($2.59/sh) vs $15.3M ($3.62/sh) in Q2 2023; adjusted net loss $16.8M ($2.86/sh).
Vicarious Surgical shareholders approve 1-for-30 reverse stock split, effective June 12, 2024
Shareholders approved reverse stock split at ratio of 1-for-30 effective June 12, 2024.
Vicarious Surgical announces 1-for-30 reverse stock split to comply with NYSE minimum share price
Reverse split ratio set at 1-for-30, approved by shareholders at June 10, 2024 annual meeting.
Vicarious Surgical reports Q1 2024 net loss of $17.0M; cash burn guidance unchanged at $50M
GAAP net loss $17.0M ($0.10/sh) vs $26.9M ($0.21) YoY; adjusted net loss $15.1M ($0.09).
Executive Chairman David Styka resigns from Vicarious Surgical board, effective Feb 29, 2024
David Styka notified Board on Feb 27 of his resignation as executive chairman and director, effective Feb 29.
Vicarious Surgical Q4 2023 GAAP net loss $13.1M; 2024 cash burn guided ~$50M
Q4 2023 GAAP net loss $13.1M ($0.06/sh); adjusted net loss $14.6M ($0.07/sh), improving from $19.9M ($0.16/sh) in Q4 2022.
Vicarious Surgical appoints Randy Clark as President; Adam Sachs remains CEO
Clark appointed President effective Jan 29, 2024; Sachs steps down as President, continues as CEO.
the Company’s Board of Directors (the “Board”) has appointed Mr. Clark to the Board, effective as of April 25, 2025, pending customary conflict checks.
On March 18, 2025, Randy Clark resigned as President of Vicarious Surgical Inc. (the “Company”), effective as of April 25, 2025.
On March 13, 2025, Vicarious Surgical Inc. (the “Company”) announced that Sarah Romano was appointed by the Board of Directors of the Company (the “Board”) as Chief Financial Officer and Treasurer of the Company, effective April 1, 2025
On February 12, 2025, John Mazzola notified the Company that he intends to retire from his position as Chief Operating Officer of Vicarious Surgical Inc. (the “Company”), effective April 1, 2025.
On January 17, 2025, Vicarious Surgical Inc. (the “Company”) entered into a consulting agreement (the “Consulting Agreement”) with William Kelly in connection with Mr. Kelly’s previously disclosed departure from his role as Chief Financial Officer of the Company.
On February 27, 2024, David Styka notified the Board of Directors (the “Board”) of Vicarious Surgical Inc. (the “Company”) of his intent to resign as executive chairman and member of the Board, effective February 29, 2024.
On January 29, 2024, Vicarious Surgical Inc. (the “Company”) announced the appointment of Randy Clark as the President of the Company, effective as of the same day
In connection with the appointment of Mr. Clark, Adam Sachs stepped down from his role as President.
Max materiality 0.95 · Median 0.60 · Most common event leadership